The identification of LTB4R, LTBP4, MPI, and TCN2, in conjunction with PSMA4, highlights the intricate heterogeneity of lung cancer and underscores the necessity for tailored therapeutic strategies. Here, PSMA4 is linked to lung carcinoma.